Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database
Authors:
Preprint
- 9 October 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal disease (CVRD) manifestations for type 2 diabetes. The incidence of the first occurring CVRD manifestation and cumulative hospitalization costs of each CVRD manifestation are not well known for type 2 diabetes without CVRD history. Methods A cohort study of all type 2 diabetes free of CVRD as of January 1st 2014, was identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurring CVRD manifestation was estimated using the cumulative incidence function, with death as a competing risk. Cumulative hospitalization costs of each CVRD manifestations were estimated from the perspective of all payers. Results From about 2 million type 2 diabetes without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women and 7% with microvascular complications history. The cumulative incidence of a first CVRD manifestation was 15.3% after 5 years of follow-up with a constant linear increase over time for all CVRD manifestations: The most frequent was CKD representing 40.6% of first occurred CVRD manifestation, followed by HF (23.0%), then PAD (13.5%), stroke (13.2%) and MI (9.7%). HF and CKD together reached about one patient out of ten after 5 years and represented 63.6% of first CVRD manifestations. The 5-year global cost of all CVRD hospitalizations was 3.9 billion euros (B€), i.e. 2,450€ per patient of the whole cohort, with an exponential increase over time for each specific CVRD manifestation. The costliest was CKD (2.0 B€), followed by HF (1.2 B€), then PAD (0.7 B€), stroke (0.6 B€) and MI (0.3 B€). Conclusions/interpretation While MI, stroke and PAD remain classic major risks of complications for CVRD-free type 2 diabetes, HF and CKD nowadays represent individually a higher risk and cost than each of these classic manifestations, and jointly represents a risk and a cost twice as high as of these three classic manifestations all together. This should encourage the development of specific HF and CKD preventive strategies.Keywords
All Related Versions
- Version 1, 2023-10-09, Research Square
- Published version: Cardiovascular Diabetology, 23 (1), 1.
This publication has 38 references indexed in Scilit:
- A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOACBritish Journal of Clinical Pharmacology, 2015
- Choice of ICD‐10 codes for the identification of acute coronary syndrome in the French hospitalization databaseFundamental & Clinical Pharmacology, 2015
- Positive Predictive Value of French Hospitalization Discharge Codes for Stroke and Transient Ischemic AttackEuropean Neurology, 2015
- Association of Cardiometabolic Multimorbidity With MortalityJAMA, 2015
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part IIEuropean Heart Journal, 2013
- Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiologyDiabetes & Vascular Disease Research, 2013
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- More ‘Malignant’ Than Cancer? Five-Year Survival Following a First Admission for Heart FailureEuropean Journal of Heart Failure, 2001
- Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populationsThe Lancet, 1999